Resumen
It refers to a composition for promoting hair growth, which comprises isolated and expanded MSCs, preferably adipose derived stem cells, ATP and a pharmaceutically acceptable vehicle. It further refers to a kit of parts comprising individual vials with MDCs and ATP. It refers also to said composition or said kit for use in androgenic alopecia. It further refers to cosmetic or non-therapeutic use of said composition or said kit for promoting hair growth. It further refers to isolated and expanded MSCs, preferably adipose derived stem cells, for use in promoting hair growth and for the prevention and/or treatment of androgenic alopecia.
Reivindicaciones
CLAIMS 1. A composition for promoting hair growth comprising a therapeutically effective amount of isolated and expanded mesenchymal stem cells (MSCs), a therapeutically effective amount of ATP (adenosine triphosphate) and a pharmaceutically acceptable vehicle, wherein the therapeutically effective dose of ATP is comprised, expressed in concentration of ATP, between about 10 pM and about 20 mM. 2. The composition according to claim 1 , wherein the therapeutically effective dose of isolated and expanded MSCs, preferably ADSCs, is comprised between about 4 x 10<4>and about 15 x 10<7>MSCs, preferably ADSCs, per mL of the pharmaceutically acceptable vehicle. 3. The composition according to any one of claims 1 or 2, wherein the therapeutically effective amount of ATP comprised in the composition, expressed in concentration of ATP, is between 50 pM and 250 pM, preferably between 75 pM and about 250 pM, still more preferably about 100 pM. 4. The composition according to any one of claims 1 to 3, wherein the MSCs are derived from adipose tissue, bone marrow, umbilical cord, placenta, amniotic fluid, peripheral blood, preferably from adipose tissue. 5. The composition according to any one of claims 1 to 4, wherein the isolated and expanded MSCs are present in the composition in a therapeutically effective amount of between 10<5>and about 10<6>cells per mL of the pharmaceutically acceptable vehicle. 6. The composition according to any one of claims 1 to 4, wherein the MSCs are present in the composition in a therapeutically effective amount of between 1 x 10<6>cells per mL and 20 x 10<6>cells per mL of the pharmaceutically acceptable vehicle, preferably in a therapeutically effective amount of between 1 x 10<6>cells per mL and 10 x 10<6>cells per mL of the pharmaceutically acceptable vehicle, more preferably in a therapeutically effective amount of between 1 x 10<6>cells per mL and 5 x 10<6>cells per mL of the pharmaceutically acceptable vehicle. 7. The composition according to any one of claims 1 to 6, wherein the mesenchymal stem cells are isolated and expanded adipose derived stem cells (ADSC), the therapeutically effective amount of ATP present in the composition, expressed in concentration of ATP, is about 100 pM, and the ADSCs are present in the composition in a therapeutically effective amount of about 10<6>cells per mL of the pharmaceutically acceptable vehicle, and the ATP can optionally be in the form of liposomated ATP. 8. The composition according to any one of claims 1 to 7, wherein the pharmaceutically acceptable vehicle is selected from hypothermic biopreservation media and infusion solutions. 9. The composition according to claim 8, wherein the pharmaceutically acceptable vehicle is selected from HypoThermosol®, HypoThermosol® FRS Preservation Media, Ringer’s solution, Ringer’s lactate solution, Hartmann’s lactate solution, saline solution, glucose solution, albumin solution, and mixtures thereof. 10. The composition according to claim 9, wherein the pharmaceutically acceptable vehicle is selected from HypoThermosol®, HypoThermosol® FRS Preservation Media, a combination of Ringer’s lactate solution and albumin, and a combination of saline solution and glucose. 11. The composition according to claim 10, wherein the pharmaceutically acceptable vehicle is selected from HypoThermosol®, and HypoThermosol® FRS Preservation Media. 12. The composition according to claim 11 , wherein the pharmaceutically acceptable vehicle is HypoThermosol® FRS Preservation Media. 13. A kit of parts comprising: a. a first vial containing a population of MSCs as defined in any one of claims 1 to 12; and b. a second vial comprising ATP at any of the concentrations defined in any one of claims 1 to 12; wherein the kit further comprises a pharmaceutically acceptable vehicle. 14. The kit of parts according to claim 13, further comprising instructions for use specifying the co-administration or sequential application of the MSCs and the ATP for promoting hair growth. 15. A composition according to any one of claims 1 to 12 or the kit of parts according to any one of claims 13 or 14, for use in the prevention or treatment of alopecia. 16. The composition for use according to claim 15, for use in the prevention or treatment of androgenic alopecia. 17. A non-therapeutic use of the composition according to any one of claims 1 to 12 or the kit of parts according to any one of claims 14 or 15, for promoting hair growth in a subject in need thereof. 18. Isolated and expanded MSCs, preferably ADSCs, for use in promoting hair growth. 19. Isolated and expanded MSCs, preferably ADSCs, for use in the prevention of androgenic alopecia and/or treatment of androgenic alopecia. 20. The composition for use according to any one of claims 15 or 16 or 18 or 19, wherein the dose of the cells to be administered is comprised between about 10<5>and about 10<6>cells combined with a concentration of ATP comprised between about 10 pM and about 20 mM, in a pharmaceutically acceptable vehicle per cm<2>of alopecic area.
